Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms

Christin E. Burd, Matthew S. Gill, Laura J. Niedernhofer, Paul D. Robbins, Steven N. Austad, Nir Barzilai, James L Kirkland

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Through the progress of basic science research, fundamental mechanisms that contribute to age-related decline are being described with increasing depth and detail. Although these efforts have identified new drug targets and compounds that extend life span in model organisms, clinical trials of therapeutics that target aging processes remain scarce. Progress in aging research is hindered by barriers associated with the translation of basic science discoveries into the clinic. This report summarizes discussions held at a 2014 Geroscience Network retreat focused on identifying hurdles that currently impede the preclinical development of drugs targeting fundamental aging processes. From these discussions, it was evident that aging researchers have varied perceptions of the ideal preclinical pipeline. To forge a clear and cohesive path forward, several areas of controversy must first be resolved and new tools developed. Here, we focus on five key issues in preclinical drug development (drug discovery, lead compound development, translational preclinical biomarkers, funding, and integration between researchers and clinicians), expanding upon discussions held at the Geroscience Retreat and suggesting areas for further research. By bringing these findings to the attention of the aging research community, we hope to lay the foundation for a concerted preclinical drug development pipeline.

Original languageEnglish (US)
Pages (from-to)1388-1394
Number of pages7
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume71
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Research
Research Personnel
Pharmaceutical Preparations
Drug Discovery
Therapeutics
Drug Delivery Systems
Biomarkers
Clinical Trials

Keywords

  • Aging
  • Geroscience network
  • Preclinical drug development

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms. / Burd, Christin E.; Gill, Matthew S.; Niedernhofer, Laura J.; Robbins, Paul D.; Austad, Steven N.; Barzilai, Nir; Kirkland, James L.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, No. 11, 01.11.2016, p. 1388-1394.

Research output: Contribution to journalArticle

Burd, Christin E. ; Gill, Matthew S. ; Niedernhofer, Laura J. ; Robbins, Paul D. ; Austad, Steven N. ; Barzilai, Nir ; Kirkland, James L. / Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms. In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2016 ; Vol. 71, No. 11. pp. 1388-1394.
@article{a6dc8a075cab46f991a1976e65f79d2f,
title = "Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms",
abstract = "Through the progress of basic science research, fundamental mechanisms that contribute to age-related decline are being described with increasing depth and detail. Although these efforts have identified new drug targets and compounds that extend life span in model organisms, clinical trials of therapeutics that target aging processes remain scarce. Progress in aging research is hindered by barriers associated with the translation of basic science discoveries into the clinic. This report summarizes discussions held at a 2014 Geroscience Network retreat focused on identifying hurdles that currently impede the preclinical development of drugs targeting fundamental aging processes. From these discussions, it was evident that aging researchers have varied perceptions of the ideal preclinical pipeline. To forge a clear and cohesive path forward, several areas of controversy must first be resolved and new tools developed. Here, we focus on five key issues in preclinical drug development (drug discovery, lead compound development, translational preclinical biomarkers, funding, and integration between researchers and clinicians), expanding upon discussions held at the Geroscience Retreat and suggesting areas for further research. By bringing these findings to the attention of the aging research community, we hope to lay the foundation for a concerted preclinical drug development pipeline.",
keywords = "Aging, Geroscience network, Preclinical drug development",
author = "Burd, {Christin E.} and Gill, {Matthew S.} and Niedernhofer, {Laura J.} and Robbins, {Paul D.} and Austad, {Steven N.} and Nir Barzilai and Kirkland, {James L}",
year = "2016",
month = "11",
day = "1",
doi = "10.1093/gerona/glw112",
language = "English (US)",
volume = "71",
pages = "1388--1394",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms

AU - Burd, Christin E.

AU - Gill, Matthew S.

AU - Niedernhofer, Laura J.

AU - Robbins, Paul D.

AU - Austad, Steven N.

AU - Barzilai, Nir

AU - Kirkland, James L

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Through the progress of basic science research, fundamental mechanisms that contribute to age-related decline are being described with increasing depth and detail. Although these efforts have identified new drug targets and compounds that extend life span in model organisms, clinical trials of therapeutics that target aging processes remain scarce. Progress in aging research is hindered by barriers associated with the translation of basic science discoveries into the clinic. This report summarizes discussions held at a 2014 Geroscience Network retreat focused on identifying hurdles that currently impede the preclinical development of drugs targeting fundamental aging processes. From these discussions, it was evident that aging researchers have varied perceptions of the ideal preclinical pipeline. To forge a clear and cohesive path forward, several areas of controversy must first be resolved and new tools developed. Here, we focus on five key issues in preclinical drug development (drug discovery, lead compound development, translational preclinical biomarkers, funding, and integration between researchers and clinicians), expanding upon discussions held at the Geroscience Retreat and suggesting areas for further research. By bringing these findings to the attention of the aging research community, we hope to lay the foundation for a concerted preclinical drug development pipeline.

AB - Through the progress of basic science research, fundamental mechanisms that contribute to age-related decline are being described with increasing depth and detail. Although these efforts have identified new drug targets and compounds that extend life span in model organisms, clinical trials of therapeutics that target aging processes remain scarce. Progress in aging research is hindered by barriers associated with the translation of basic science discoveries into the clinic. This report summarizes discussions held at a 2014 Geroscience Network retreat focused on identifying hurdles that currently impede the preclinical development of drugs targeting fundamental aging processes. From these discussions, it was evident that aging researchers have varied perceptions of the ideal preclinical pipeline. To forge a clear and cohesive path forward, several areas of controversy must first be resolved and new tools developed. Here, we focus on five key issues in preclinical drug development (drug discovery, lead compound development, translational preclinical biomarkers, funding, and integration between researchers and clinicians), expanding upon discussions held at the Geroscience Retreat and suggesting areas for further research. By bringing these findings to the attention of the aging research community, we hope to lay the foundation for a concerted preclinical drug development pipeline.

KW - Aging

KW - Geroscience network

KW - Preclinical drug development

UR - http://www.scopus.com/inward/record.url?scp=84994441052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994441052&partnerID=8YFLogxK

U2 - 10.1093/gerona/glw112

DO - 10.1093/gerona/glw112

M3 - Article

C2 - 27535964

AN - SCOPUS:84994441052

VL - 71

SP - 1388

EP - 1394

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 11

ER -